Researchers in Dublin believe they have discovered that triple-negative breast cancer cells may respond to a new compound that disrupts their signaling process.
Triple-negative breast cancer is one of the more difficult forms of the disease to treat, and as MedicalDaily.com
reports, there is no current targeted therapy for the illness.
Scientists claim that there are high levels of epidermal growth factor receptors (EGFR) in triple-negative breast cancer. They have found a compound that disrupts these receptors from receiving signals from the cancer cells.
"One reason for the poor prognosis for this group is the lack of targeted therapies for these women. Having found that an ADAM inhibitor can reduce the proliferation of TNBC cell lines, we hope that ADAMs may be a useful therapeutic target," Dr. Patricia McGowan, senior postdoctoral scientist on the study, told the news source.
Researchers are pleased with the results they have seen so far in reducing the progression of the disease, and hope that this form of therapy may be a useful treatment in fighting the illness.
One in eight women have the chance of developing breast cancer in their lifetime, according to the American Cancer Society.